Kaya Ltd.
Snapshot View

489.80 -1.10 ▼-0.2%

04 August 2021, 04:00:00 P.M.
Volume: 9,949

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.kaya.in
Financial Indicators
Market Cap 639.88 Cr.
Earnings per share (EPS) -15.78 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-06
Industry PE 202.10 Trailing Twelve Months Ending 2021-06
Book Value / Share 30.99 Trailing Twelve Months Ending 2021-06
Price to Book Value 15.81 Calculated using Price: 489.80
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.31 Cr. 13,064,091 Shares
FaceValue 10
Company Profile

Kaya started its journey on March 27, 2003. It now has a range of Kaya Clinics across India and Middle East. In addition to that, it also has 100 plus product retail outlets called Kaya Skin Bar in India.

In order to tap the increasing need of looking naturally good, Kaya opened its first clinic in 2002. The objective was straight, and that is to deliver flawless skin to both men and women. Today, Kaya Clinics successfully offer best skin and hair care solutions that enhance the look and feel of your skin and hair beautifully. All of this takes place in our state-of-the-art and ambient clinics. Plus, the services that they offer are designed and supervised by a team of experts that include trained dermatologists and beauty therapists. Kaya's experts have also put forward in-depth research to develop products from 13 distinct skin care ranges. It is their concrete formulations that add to the efficiency of the products in order to meet customers’ customized beauty needs.

Business area of the company:

The company offers various skin care services and beauty treatments.

Services:

• skin glow facials
• fairness and de-pigmentation
• anti-acne and blemishes
• youthful skin
• laser hair reduction
• kaya bridal, men, and hair care,etc.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.22%
1 Week
+0.78%
1 Month
+47.62%
3 Month
+83.45%
6 Month
+45.88%
1 Year
+136.96%
2 Year
+23.08%
5 Year
-37.58%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -84.05 50.12 20.90 3.76 -11.41 -8.68 -7.57 -46.11
Return on Capital Employed (%) 3.79 -4.89 22.58 16.56 5.43 -9.62 -5.06 -4.65 -7.24
Return on Assets (%) -0.11 -4.61 9.99 8.99 2.24 -6.51 -4.87 -3.93 -14.21

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds -29 66 83 235 251 229 210 158 82
Non Curr. Liab. 204 127 121 15 18 5 2 10 142
Curr. Liab. 93 227 125 129 142 190 137 180 189
Minority Int. 0 2 2 1 1
Equity & Liab. 268 420 329 378 412 425 351 349 413
Non Curr. Assets 230 309 105 143 181 239 231 234 318
Curr. Assets 38 111 224 235 231 187 120 115 95
Misc. Exp. not W/O
Total Assets 268 420 329 378 412 425 351 349 413

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 130 143 290 332 370 409 400 421 393
Other Income 17 19 81 15 12 11 10 4 9
Total Income 147 162 372 348 382 420 410 425 402
Total Expenditure -130 -151 -274 -296 -352 -425 -398 -406 -338
PBIDT 16 11 97 52 30 -4 12 19 64
Interest -2 -2 -4 -4 -4 -5 -7 -9 -22
Depreciation -10 -10 -9 -12 -17 -20 -24 -29 -75
Taxation -4 -4 -9 3 0 6 -21
Exceptional Items -1 -11 -37 -5
PAT 0 -16 37 32 9 -27 -19 -14 -54

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 26 34 92 29 5 -8 -12 22 47
Cash Fr. Inv. -20 -132 -11 -17 -6 -42 24 -28 -12
Cash Fr. Finan. -10 115 -73 0 0 33 -7 5 -47
Net Change -3 18 7 13 -2 -16 6 -1 -12
Cash & Cash Eqvt 7 25 14 28 28 14 20 19 7

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 59.93 59.93 59.93 59.93 59.93 59.93 59.93 59.38 59.93
Public 40.07 40.07 40.07 40.07 40.07 40.07 40.07 40.62 40.07
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 03 Aug 2021
Announcement under Regulation 30 (LODR)-Change in Directorate
Board of Directors of Kaya Limited at its meeting held today i.e. Tuesday August 3 2021 has interalia

a. approved the un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2021. The financial results and statutory auditors limited review report thereon are enclose as Annexure I.

b. approved the appointment of Dr. Om Manchanda (DIN : 02099404) as an Additional Director (Independent) of the Company for a period of 5 (five) years with effect from August 3 2021 subject to the approval of the shareholders of the Company at the general meeting. A brief profile of Dr. Manchanda is enclosed as Annexure II.

c. approved the appointment of Ms. Vasuta Agarwal (DIN : 07480674) as an Additional Director (Independent) of the Company for a term of 5 (five) years with effect from August 3 2021 subject to the approval of the shareholders of the Company at the general meeting. A brief profile of Ms. Agarwal is enclosed as Annexure III.
Tue, 03 Aug 2021
Outcome Of Board Meeting Held Today I.E. August 3 2021
the Board of Directors of Kaya Limited at its meeting held today i.e. Tuesday August 3 2021 has interalia
a. approved the un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2021. The financial results and statutory auditors limited review report thereon are enclose as Annexure I.
b. approved the appointment of Dr. Om Manchanda (DIN : 02099404) as an Additional Director (Independent) of the Company for a period of 5 (five) years with effect from August 3 2021 subject to the approval of the shareholders of the Company at the general meeting. A brief profile of Dr. Manchanda is enclosed as Annexure II.
c. approved the appointment of Ms. Vasuta Agarwal (DIN : 07480674) as an Additional Director (Independent) of the Company for a term of 5 (five) years with effect from August 3 2021 subject to the approval of the shareholders of the Company at the general meeting. A brief profile of Ms. Agarwal is enclosed as Annexure III.
Tue, 03 Aug 2021
Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed performance update on the financial results of the Company for the quarter ended June 30 2021.

Kindly take the above on record.

Technical Scans View Details

Tue, 03 Aug 2021
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
William %R Trending Down William %R Trending Down
Mon, 02 Aug 2021
High Delivery Percentage High Delivery Percentage

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.75 -1.1%
Divi's Laboratories Ltd. 131,785.24 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,768.80 +1.0%
Cipla Ltd. 75,796.16 939.65 +1.2%
Cadila Healthcare Ltd. 60,170.47 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,066.40 -0.6%
Piramal Enterprises Ltd. 57,915.28 2,550.50 +1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 31.52 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,550.50 +1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 4.15 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,550.50 +1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 0.10 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 14.13 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,550.50 +1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 17.85 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,550.50 +1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,550.50 +1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.75 -1.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,964.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,768.80 +1.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 939.65 +1.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 587.75 -0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,066.40 -0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,550.50 +1.7%